Conference Coverage (ASCO)

Allovectin-7 Cancer Gene Therapy Completes Phase II Studies

Published in Gene Therapy Weekly, June 8th, 1998

A phase II study showed that Allovectin-7 cancer gene therapy for metastatic malignant melanoma was safe and induced clinically significant tumor regression.

Researchers from several clinical centers participated in phase I/II studies of intratumoral injection of Allovectin-7 which is an HLA-B7/(beta)2M plasmid DNA/lipid complex. Evan M. Hersh of the Arizona Cancer Center represented the clinical teams and presented study results at the 34th Annual Meeting of the American Society of Clinical Oncology, held May 16-19, 1998, in Los Angeles, California (abstract "Allovectin-7 (HLA-B7/(beta)2M Plasmid DNA/Lipid Complex) Therapy in Metastatic Malignant Melanoma, Phase II...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry